 Trxade Group, Inc. NASDAQ: MEDS, an integrated drug procurement, delivery and healthcare platform, announced today that its wholly-owned subsidiary, Integra Pharma Solutions, LLC, has formally withdrawn its Emergency Use Authorization EUA application in connection with its partners manufacture of the SARS-CoV-2 IgMIgG Antibody Rapid Test Kit from consideration in response to U.S. Food and Drug Administration FDA guidance. The decision to withdraw the EUA application was made after much discussion with its partnered manufacturer. Per FDA guidance, only one EUA application is allowed per manufactured kit product. 